Sun Pharmaceuticals eyes acquiring US-based Organon

Sun Pharmaceutical, India’s largest pharma firm, is reportedly evaluating a USD 10 bn acquisition of US-based women’s health specialist Organon, Economic Times reports, citing sources in the know. If successful, it would be the largest cross-border acquisition by an Indian pharma company and the firm’s most ambitious since its merger withRanbaxy.

Why it matters: Sun Pharmaceutical is a significant player in the MENA market, particularly the UAE and Egypt. It established a manufacturing unit in Egypt in 2017. In the UAE, the company has operated for two decades, including through contract manufacturing partnerships with local firms in production, batch releases, and packaging.

LNK Energy launched with INR 100 bn investment plan

LNK Energy, an integrated clean energy platform founded by three Indian entrepreneurs, has been launched with an investment plan of INR 100 bn over the next five years. The company was announced on the sidelines of the World Economic Forum Annual Meeting in Davos.

Project details: The platform will begin operations with a 6 GW solar cell and module manufacturing facility with integrated ingot and wafer production in Maharashtra. The first project will produce high-efficiency solar cells and modules. The company plans to expand into green fuels, with a focus on green hydrogen, and build a renewable energy generation portfolio as an independent power producer through hybrid open access models. It also plans to manufacture related components, including junction boxes, battery platforms, and energy storage systems.

Tags: